Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study
| Autor: | Fernandez Rivera, Constantino, Calvo Rodriguez, Maria, Poveda JL, Pascual, Julio, Crespo, Marta, Gomez, Gonzalo, Cabello Pelegrin, Sheila, Paul, Javier, Lauzurica, Ricardo, Perez Mir, Monica, Moreso, Francesc, Perello, Manel, Andres, Amado, Gonzalez, Esther, Fernandez, Ana, Mendiluce, Alicia, Fernandez Carbajo, Beatriz, Sanchez Fructuoso, Ana, Calvo, Natividad, Suarez, Alejandro, Bernal Blanco, Gabriel, Osuna, Antonio, Ruiz-Fuentes MC, Melilli, Edoardo, Montero Perez, Nuria, Ramos, Ana, Fernandez, Beatriz, Lopez, Veronica, Hernandez, Domingo, Better Study |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Graft Rejection
medicine.medical_specialty Urology Biological Availability Renal function chemical and pharmacologic phenomena Tacrolimus Drug Administration Schedule Cmin Pharmacokinetics Humans Medicine Prospective Studies Adverse effect tacrolimus treatment failure Transplantation business.industry renal transplantation Kidney Transplantation Transplant Recipients Discontinuation Bioavailability clinical practice Regimen business bioavailability pharmacokinetics Immunosuppressive Agents |
| Zdroj: | CLINICAL TRANSPLANTATION r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname Clinical Transplantation r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol |
| ISSN: | 0902-0063 |
| Popis: | Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus®) and 89 in the PR-Tac (Advagraf®) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs PR-Tac (61% increase; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text